News

A commitment to complete post-marketing trials has become a condition of approval for many drugs and this trial was expected to take three to four years to complete.

The agreement includes the rights to use Neisseria meningitidis group Y and Haemophilus influenzae type b (Hib) components for the new vaccines These new vaccine candidates are expected

The ruling involves a patent covering the calcium salt of atorvastatin, the active ingredient in Lipitor, which expires in July 2010. Pfizer said that the ruling on the

“The continued advancement of the HIF-1 alpha program demonstrates our commitment to developing a differentiated cancer portfolio,” said Jeffrey Buchalter, chairman and CEO of Enzon. HIF-1 alpha is

Following the conclusion of the review, the opinion for Januvia will be transmitted to the European Commission (EC). If the EC adopts the opinion, Januvia will be the

The European Commission is expected to issue a final decision within approximately six weeks. Xyrem has been designated as an orphan medicinal product. Orphan medicinal products are used

The studies, designed to expand the use of the drug, included examining the effectiveness of the drug in patients undergoing elective spinal fusion surgery, pneumonectomy or esophagectomy for

The trial will compare treatment with galiximab in combination with rituximab(Genentech/Biogen Idec's Rituxan), to rituximab in combination with placebo in patients with follicular non-Hodgkin's lymphoma (NHL) that has

P53 plays critical role in the development of many tumors and it is mutated in many cancers. Researchers have identified compounds that restore p53 , but it has